Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Nested Therapeutics, Inc
Pfizer
Pfizer
Ikena Oncology
National Cancer Institute (NCI)
Deciphera Pharmaceuticals, LLC
M.D. Anderson Cancer Center
Polaris Group
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Duke University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
TransMolecular